AI Article Synopsis

Article Abstract

Patients with pediatric cancer receive radiotherapy to cure several types of cancer, requiring computed tomography simulation (CT sim) for precise treatment. However, there is currently no suitable framework to reduce the inherent delays in CT sim. The present study aimed to identify the underlying causes of the delays in CT sim regarding three different time periods (duration of patient admission to CT sim, diagnosis to treatment and CT sim to treatment) among patients with pediatric cancer. A total of 58 patients with pediatric cancer who received radiation therapy under anesthesia at King Abdulaziz University Hospital (Jeddah, Saudi Arabia) between 2016 and 2021 (60 months) were included in the current study. The underlying cause of delays regarding three separate time periods was determined according to patient type, diagnosis, therapy type and year of diagnosis. The CT sim processing time averaged 73 days and was received by patients after 28.96±28.5 days. The major delays in terms of frequency and length of duration between different time points such as patient admission and CT sim, interval between diagnosis and treatment, and duration between CT sim and therapy were (mean±SD) 37.13±29.9, 58.08±24.9 and 28.15±7.9 days, respectively. Machine availability, instability of the patients' medical condition and intensity-modulated radiation therapy (IMRT) caused 66.6% of the delays. In conclusion, outpatients may experience CT sim delays. Machine availability, conditions of patients and IMRT treatment were the major reasons to cause the delay in CT sim. Strategies should be employed to prevent CT sim delays and improve patient experience.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11056923PMC
http://dx.doi.org/10.3892/ol.2024.14405DOI Listing

Publication Analysis

Top Keywords

patients pediatric
16
pediatric cancer
16
sim
11
delays sim
8
underlying delays
8
time periods
8
patient admission
8
admission sim
8
diagnosis treatment
8
radiation therapy
8

Similar Publications

Atopic dermatitis (AD) is a common chronic inflammatory skin disorder globally. Crisaborole, a nonsteroidal topical phosphodiesterase 4 inhibitor (PDE4i), has been utilized in treating AD. Crisaborole regulates the production of inflammatory cytokines, which are usually overactive among AD patients.

View Article and Find Full Text PDF

Use of the Adaptive Behaviour Dementia Questionnaire in a Down Syndrome Specialty Clinic.

J Integr Neurosci

January 2025

Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA.

Objective: To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome.

Study Design: A retrospective chart review of patients with Down syndrome was conducted to follow the use of the Adaptive Behaviour Dementia Questionnaire (ABDQ) in a dementia screening protocol. The ABDQ results for patients aged 40 years and older at a Down syndrome specialty clinic program were assessed.

View Article and Find Full Text PDF

Background: Autism spectrum disorder (ASD) has been reported to confer an increased risk of natural premature death. Telomere erosion caused by oxidative stress is a common consequence in age-related diseases. However, whether telomere length (TL) and oxidative indicators are significantly changed in ASD patients compared with controls remains controversial.

View Article and Find Full Text PDF

Purpose: Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition that affects approximately 5% of the pediatric population, with increased prevalence among those with type 1 diabetes (T1D). Reports suggest that unrecognized and untreated ADHD impairs T1D control and that ADHD may be underdiagnosed in the Polish population. The International Society for Pediatric and Adolescent Diabetes recommends neurodevelopmental assessments in children with T1D, but specific guidelines on procedures and implementation are lacking.

View Article and Find Full Text PDF

The recent U.S. Food and Drug Administration guidance on complex innovative trial designs acknowledges the use of Bayesian strategies to incorporate historical information based on clinical expertise and data similarity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!